'FDA panel votes against Capricor's Duchenne heart disease therapy'- Reuters
https://www.reuters.com/business/healthcare-pharmaceuticals/fda-panel-votes-against-capricors-duchenne-heart-disease-therapy-2026-07-29/
A group of experts told the FDA they don't think Capicor's new medicine for a heart disease is ready to use. When experts say no to a medicine, it's a sign the company's plan hit a bump, so watch how the stock and the company respond next.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.